Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders

Minoru Yoshida, Kazuo Tamura, Masahiro Imamura, Yoshiro Niitsu, Takeshi Sasaki, Akio Urabe, Kazuma Ohyashiki, Tomoki Naoe, Akihisa Kanamaru, Mitsune Tanimoto, Tohru Masaoka

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This prospective multicenter study was performed to clarify the efficacy and safety of micafungin (MCFG) as an empirical antifungal therapy for suspected fungal infection in patients with hematological disorders and neutropenia. Three hundred and eighty-eight patients were enrolled; 151 patients with possible fungal infection diagnosed by radiological imaging or serological testing and 237 patients with refractory fever were included in this study. The mean dose and duration of treatment with MCFG were 154.6 mg/day and 14.0 days, respectively. The clinical response rate for patients with possible fungal infection and refractory fever was 60.1% and 65.3%, respectively. Even in persistent neutropenic patients with a neutrophil count of

Original languageEnglish
Pages (from-to)449-457
Number of pages9
JournalAnnals of Hematology
Volume91
Issue number3
DOIs
Publication statusPublished - Mar 2012

    Fingerprint

Keywords

  • Echinocandin
  • Empirical therapy
  • Febrile neutropenia
  • Fungal infection
  • Hematological disorders
  • Micafungin

ASJC Scopus subject areas

  • Hematology

Cite this

Yoshida, M., Tamura, K., Imamura, M., Niitsu, Y., Sasaki, T., Urabe, A., Ohyashiki, K., Naoe, T., Kanamaru, A., Tanimoto, M., & Masaoka, T. (2012). Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders. Annals of Hematology, 91(3), 449-457. https://doi.org/10.1007/s00277-011-1316-y